Hyperbaric oxygen and radiotherapy: clinical experiences.

I. Churchill-Davidson
{"title":"Hyperbaric oxygen and radiotherapy: clinical experiences.","authors":"I. Churchill-Davidson","doi":"10.1159/000386963","DOIUrl":null,"url":null,"abstract":"From June, 1955 to April, 1965, a total of 235 patients whose tumours were so locally advanced that they were considered to have little, or no chance of cure by conventional radiotherapy, have been irradiated while they breathed oxygen at 3–4 atmospheres absolute pressure (29.4–44.1 lb/sq.in. gauge pressure). Although a fully randomised control series has not been possible, 81 patients with equally advanced disease, who for various reasons were unsuitable for treatment in the pressure chamber have, since July, 1957, been treated with the same dosage and fractionation while breathing air at atmospheric pressure. Comparable evaluation of both series shows the survival is twice as great among those patients treated in high pressure oxygen as it is in those treated in air. Also, 68 First Annual San Francisco Cancer Symposium whereas no patients treated in air have so far been free from recurrence for more than 4 years, an average of 11% of patients treated in oxygen have been free from recurrence for periods of up to 9 years. Especially good results have been obtained in treating tumours of the head and neck and uterine cervix. The response of secondary squamous carcinoma in lymph nodes is very markedly improved by using high pressure oxygen. Moreover, the difference in the rate of sterilisation of the growth in the irradiated area is even greater than the difference in the humber of long term survivors. Comparative figures for sterilisation are: Primary growth: H.P.0.2–56%, Air – 14%. Glands (head and neck tumours): H.P.0.2 – 73%, Air – 25%. From the Columbia – Presbyterian Medical Center, New York City Clinical Aspects of Hyperbaric Oxygen and Radiotherapy New York Experiences By C. H. Chang The role of oxygen as a powerful modifier of radiation injury in the biological system has been well recognized. However, a significant improvement in clinical result in the radiotherapy of human cancer with hyperbaric oxygen has not yet been established. A clinical study of this kind is difficult because of variations in radiation treatment technique, oxygen pressure, fractionation and case material. Of special interest in the clinical study is the degree of normal tissue reaction, the tolerance of patients to the procedure, the complication and finally the cure rate. Of special importance is the plan of the clinical trial and study for maximum information which should be worked out with bio-statisticians before starting the clinical project. O. Our experience with hyperbaric oxygen at the Columbia-Presbyterian Medical Center consists of an initial pilot study and subsequent randomization of patients with advanced cancer of the head and neck using hyperbaric oxygen at 4 atmospheres from 1960 to 1963 and an extension of","PeriodicalId":19371,"journal":{"name":"Nuntius radiologicus","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"1969-10-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"7","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nuntius radiologicus","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1159/000386963","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 7

Abstract

From June, 1955 to April, 1965, a total of 235 patients whose tumours were so locally advanced that they were considered to have little, or no chance of cure by conventional radiotherapy, have been irradiated while they breathed oxygen at 3–4 atmospheres absolute pressure (29.4–44.1 lb/sq.in. gauge pressure). Although a fully randomised control series has not been possible, 81 patients with equally advanced disease, who for various reasons were unsuitable for treatment in the pressure chamber have, since July, 1957, been treated with the same dosage and fractionation while breathing air at atmospheric pressure. Comparable evaluation of both series shows the survival is twice as great among those patients treated in high pressure oxygen as it is in those treated in air. Also, 68 First Annual San Francisco Cancer Symposium whereas no patients treated in air have so far been free from recurrence for more than 4 years, an average of 11% of patients treated in oxygen have been free from recurrence for periods of up to 9 years. Especially good results have been obtained in treating tumours of the head and neck and uterine cervix. The response of secondary squamous carcinoma in lymph nodes is very markedly improved by using high pressure oxygen. Moreover, the difference in the rate of sterilisation of the growth in the irradiated area is even greater than the difference in the humber of long term survivors. Comparative figures for sterilisation are: Primary growth: H.P.0.2–56%, Air – 14%. Glands (head and neck tumours): H.P.0.2 – 73%, Air – 25%. From the Columbia – Presbyterian Medical Center, New York City Clinical Aspects of Hyperbaric Oxygen and Radiotherapy New York Experiences By C. H. Chang The role of oxygen as a powerful modifier of radiation injury in the biological system has been well recognized. However, a significant improvement in clinical result in the radiotherapy of human cancer with hyperbaric oxygen has not yet been established. A clinical study of this kind is difficult because of variations in radiation treatment technique, oxygen pressure, fractionation and case material. Of special interest in the clinical study is the degree of normal tissue reaction, the tolerance of patients to the procedure, the complication and finally the cure rate. Of special importance is the plan of the clinical trial and study for maximum information which should be worked out with bio-statisticians before starting the clinical project. O. Our experience with hyperbaric oxygen at the Columbia-Presbyterian Medical Center consists of an initial pilot study and subsequent randomization of patients with advanced cancer of the head and neck using hyperbaric oxygen at 4 atmospheres from 1960 to 1963 and an extension of
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
高压氧与放疗:临床经验。
从1955年6月到1965年4月,共有235例肿瘤局部进展严重,被认为通过常规放射治疗几乎没有治愈机会的患者,在3-4个大气压(29.4-44.1磅/平方英寸)的绝对压力下呼吸氧气进行放射治疗。表压)。尽管不可能进行完全随机对照,但自1957年7月以来,81例因各种原因不适合在压力室治疗的同样晚期疾病患者在呼吸常压空气的同时接受了相同剂量和分离治疗。两个系列的可比评估显示,在高压氧气治疗的患者的生存率是在空气中治疗的患者的两倍。同样,68年第一届旧金山癌症研讨会上,虽然目前为止在空气中治疗的患者中没有一个在4年以上的时间里没有复发,但在氧气中治疗的患者中,平均有11%的患者在长达9年的时间里没有复发。在治疗头颈部和子宫颈肿瘤方面取得了特别好的效果。高压氧治疗对继发性淋巴结鳞癌的治疗效果有显著改善。此外,受辐照地区生长的绝育率的差异甚至大于长期幸存者数量的差异。灭菌的比较数据如下:初级增长:hp 0.2 - 56%, Air - 14%。腺体(头颈部肿瘤):hp 0.2 - 73%, Air - 25%。来自哥伦比亚-长老会医学中心,纽约高压氧和放射治疗的临床方面的经验在生物系统中,氧作为一种强大的辐射损伤调节剂的作用已经得到了很好的认识。然而,高压氧对人类癌症放疗的临床效果的显著改善尚未得到证实。由于放射治疗技术、氧压、分离和病例材料的变化,这类临床研究是困难的。临床研究中特别关注的是正常组织反应的程度、患者对手术的耐受性、并发症以及最终的治愈率。特别重要的是临床试验和研究计划,以获得最大的信息,这应该在开始临床项目之前与生物统计学家一起制定。我们在哥伦比亚长老会医学中心的高压氧经验包括最初的试点研究和随后的随机头颈部晚期癌症患者,从1960年到1963年使用4个大气压的高压氧,并延长
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Hyperbaric oxygen and radiotherapy: clinical experiences. [Importance of supraclavicular lymph nodes opacified during lymphography via the pedal route]. [Mammary chromothermography with encapsulated liquid crystals. Elements of the method]. [Telepelvicephaloradiometry]. [Opacification of the terminal segment of the thoracic duct and of the supraclavicular lymph nodes in lymphography through the foot. (Morphological and functional aspects)].
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1